Anti-SET (aa 50-150) polyclonal antibody

Antibody Isotype

IgG

Species Reactivity

Mouse; Human

Immunogen

Synthetic peptide conjugated to KLH derived from within residues 50 - 150 of Human SET.

Conjugate

Application Notes

IHC-P: 1 μg/ml; IHC/IF: 1/200.

Alternative Names

SET; SET nuclear oncogene; SET translocation (myeloid leukemia associated); protein SET; 2PP2A; IPP2A2; PHAPII; protein phosphatase type 2A inhibitor; Template Activating Factor I; chromatin remodelling factor; HLA-DR-associated protein II; phosphatase 2A

Entrez Gene ID

UniProt ID

Antigen Description

Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone binding. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins; however, isoform 2 specific activity is higher.

Pathway

Gene Expression; Regulation of mRNA Stability by Proteins that Bind AU-rich Elements; Stabilization of mRNA by HuR;